ImmunoVaccine (IMV) has notable insider buying

ImmunoVaccine (T:IMV)

ImmunoVaccine Inc. (IMV) has a high amount of executive buying compared to its small-cap peers over the past three months. Andrew J. Sheldon, a Director, acquired 25,000 Common Shares on a direct ownership basis at a price of $0.720 through an exercise of warrants on April 24th, 2017. The insider also acquired 25,000 Common Shares on a direct ownership basis at a price of $1.250 through the public market on April 25th, 2017. This represents a $49,250 investment into the company's shares and an account share holdings change of 44.6%.

Immunovaccine Inc. is a clinical-stage biopharmaceutical company. The Company develops products based on its vaccine enhancement platform with a primary focus on T lymphocytes (T cell) activating therapies for cancer. The Company's DepoVax adjuvanting/delivery platform produces immune response that has a specific and sustained immune effect and enables the Company to pursue vaccine candidates in cancer, infectious diseases and other vaccine applications. The DepoVax platform is used in multiple vaccine candidates, including over two-cancer vaccine candidates that have completed Phase I clinical trials. Its lead cancer vaccine, DPX- Survivac, is tested in a company-sponsored Phase II trial in lymphoma and a Phase Ib trial in ovarian cancer. Its infectious disease vaccine against respiratory syncytial virus (RSV) is in a Phase I clinical trial in Halifax, Nova Scotia.